Physician profile
Andy Lee
NPI 1013250463
$36,197.21
in general payments reported to CMS, 2019-2025
20 companies · $1,445 in 2025
The $1,445 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $11.17 · 2021: $663 · 2022: $1,035 · 2023: $30K · 2024: $1,430 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Travel and Lodging: $14K · Food and Beverage: $3,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,937.50 |
| Travel and Lodging | $13,731.75 |
| Food and Beverage | $3,614.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $15,937.50 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Eli Lilly and Company | $13,313.54 | 2023 | |
| Novartis Pharmaceuticals Corporation | $2,201.87 | 2021-2025 | |
| Abbott Laboratories | $1,597.58 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $814.32 | 2022-2025 | Impella |
| Merck Sharp & Dohme LLC | $597.47 | 2019 | |
| Novo Nordisk INC | $474.62 | 2023-2024 | Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $297.97 | 2021-2024 | |
| Gilead Sciences, INC. | $236.37 | 2019 | |
| Ancora Heart, INC. | $203.28 | 2024-2025 | Accucinch |
| Amgen INC. | $125.00 | 2022 | |
| Esperion Therapeutics, INC. | $123.95 | 2022 | |
| Allergan, INC. | $47.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.04 | 2023 | Jardiance |
| Terumo Medical Corporation | $39.90 | 2023 | Tr Band, Angio-Seal, Glidewire |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $32.97 | 2025 | Evkeeza |
| Boston Scientific Corporation | $31.67 | 2019-2020 | |
| Lilly USA, LLC | $30.89 | 2023 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $27.93 | 2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $16.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.